CoraDoc Review
Best for: Shoppers wanting low flat-fee compounded GLP-1 nationwide with no subscription
CoraDoc is a nationwide (all 50 states) doctor-prescribed GLP-1 weight-loss telehealth service offering compounded semaglutide (from $99/mo) and tirzepatide (from $165/mo) as flat, no-subscription programs. Its 'Triple Free Promise' includes a free provider visit, free 2-day shipping, and free supplies, with a full refund if not approved. It accepts HSA/FSA and Afterpay/Klarna/Affirm. Medications are compounded; a full legal suite is published and the site states it is LegitScript Certified, not independently verified here. The compounding pharmacy and legal entity are not named.
What the monthly price covers
Medication
Included
Provider visits
Included
Shipping
Included
Lab work
Not disclosed
Coaching
Not disclosed
No insurance needed · Vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
CoraDoc is one of the most affordable GLP-1 options on the market.
CoraDoc at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $99/mo
- What's included
- Medication · Consult · Shipping
- FDA status
- No FDA warning letter on record
How we scored CoraDoc
Each dimension is scored algorithmically from CoraDoc’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.
Value25%
8.7/10At $99/mo, CoraDoc runs about 41% below the $169 median for GLP-1 providers.
Effectiveness25%
7.7/10CoraDoc offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes.
User Experience15%
7.0/10Online intake and platform experience — consult included in the price; 8 platform features disclosed.
Trust & Safety15%
6.9/10Core details confirmed by our editors; no FDA warning letters on file (last checked 2026-06-22).
Accessibility10%
8.3/10CoraDoc treats patients in all 50 states. FSA/HSA cards are accepted.
Support10%
5.5/10CoraDoc provides standard clinician follow-up; no extended coaching or community program is disclosed.
How we verified this CoraDoc review
Last checked 2026-06-22- Confirmed current pricing across 2 dose/plan tiers
- Confirmed availability in all 50 states
- Confirmed what the monthly price does and doesn't include
- Checked the FDA warning-letter database for enforcement actions
- Walked the public intake/checkout flow on the provider's site
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: medium.
GLP-1 medications CoraDoc offers
Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.
Pricing
Ready to get started?
Plans and promotions change often — check CoraDoc's current pricing and active discounts before you decide.
What we like
- Low flat pricing — compounded semaglutide from $99/mo, tirzepatide from $165/mo, no subscription
- Triple Free Promise: free provider visit, free 2-day shipping, and free supplies included
- Available in all 50 states; HSA/FSA plus Afterpay/Klarna/Affirm; full refund if not approved
- Full legal suite published (Terms, Privacy, Refund Policy); board-certified providers
Watch-outs
- Lowest $99 price is the longest-commitment tier (programs range about $99-$199/mo)
- Compounding pharmacy partner not named
- 'LegitScript Certified' is stated prominently but was not independently verified here
- Operating legal entity not clearly named on the site
Is CoraDoc worth it? Our verdict
CoraDoc positions itself around one thing: Shoppers wanting low flat-fee compounded GLP-1 nationwide with no subscription. It runs $99/month — toward the affordable end of the market. It treats patients in all 50 states, so access isn't a barrier.
How much CoraDoc actually costs
- Compounded semaglutide — $99/month
- Compounded tirzepatide — $165/month
That puts CoraDoc below the roughly $169 median ongoing price across the GLP-1 providers we track — a real cost advantage.
Medications: what CoraDoc prescribes
CoraDoc prescribes semaglutide (the active drug in Wegovy and Ozempic) and tirzepatide (the active drug in Zepbound and Mounjaro) — the two molecules with the strongest published weight-loss trial outcomes. These are dispensed as compounded formulations from a licensed pharmacy, which is how the price stays below brand-name pens. Compounded drugs aren't FDA-approved as finished products — the standard trade-off across the compounded-GLP-1 market.
Who CoraDoc is best for — and who should skip it
A good fit if you…
- are focused on the lowest ongoing monthly cost.
- live anywhere in the US and want guaranteed access.
Look elsewhere if you…
- specifically want an FDA-approved brand-name pen.
- need to bill insurance — like most of this market, it's cash-pay.
Trust, safety, and medical oversight
CoraDoc treats patients in all 50 states. We found no FDA warning letters on file for the provider. As with any compounded program, the most important step you can take is confirming which licensed pharmacy fills your prescription and what's in the formulation — we explain how in our scoring methodology.
Bottom line
CoraDoc earns its place on the shortlist mainly on price: at $99/month it's one of the more affordable ways to stay on a GLP-1, without obvious corners cut on access or oversight.
Ready to start with CoraDoc?
Starting at $99/month. See current pricing and start your free consultation.
Alternatives to CoraDoc
Editorial score · methodology
Enhance MD
Best for: lab-monitored compounded GLP-1 with mandatory video visit
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this CoraDoc review:
Sources & methodology — as of June 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Ready to start with CoraDoc?
Starting at $99/month. See current pricing and start your free consultation.